A growing subset of patients with type 1 diabetes are developing insulin resistance, which may accelerate progression toward steatohepatitis, fibrosis, and CV complications via unique mechanisms.
Understand the critical role of immunometabolic dysregulation, chronic inflammation, oxidative stress, and epigenetic regulation in cardiometabolic heart failure with preserved ejection fraction
A woman with morbid obesity caused by a homozygous mutation in the LEP gene achieved a reduction in BMI of 40 kg/m2 and improvement in associated metabolic comorbidities after 4 years of metreleptin therapy.
Guidance for clinicians on various aspects of metabolic surgery for type 2 diabetes, from terminology and mechanisms of action to predictors of remission, monitoring and special considerations, and remission and recurrence.
Low free thyroxine levels and isolated hypothyroxinemia, but not subclinical hypothyroidism, are associated with an increased risk for gestational diabetes.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
With the growing importance of primary care in diabetes, this podcast discusses the evidence on continuous glucose monitoring (CGM) use, the role of primary healthcare, and practical tips for interpreting the ambulatory glucose profile (AGP) report.
A woman with morbid obesity caused by a homozygous mutation in the LEP gene achieved a reduction in BMI of 40 kg/m2 and improvement in associated metabolic comorbidities after 4 years of metreleptin therapy.
Vigilance is key in people with type 1 diabetes who take tirzepatide. In this patient, ketoacidosis developed after malaise, aphagia, and malnutrition decreased his insulin requirements and he couldn’t manage his pump and sensor.
Metabolic disorders, like hyperlipidemia and diabetes, are high-risk factors for developing retinal artery occlusion. Timely intra-arterial thrombolysis in this case was crucial for preserving the patient's vision.
In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion.
Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity. He covers what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus what's in the pipeline in terms of drug development and the indications that GLP-1 medicines may be used to treat in the future.
Diabetic retinopathy (DR) is a common diabetes condition that contributes significantly to vision impairment and blindness in working-age people. The classical theory contends that DR is solely a retinal microvascular disorder. Nevertheless, a …
Cardiovascular disease (CVD) remains the leading cause of death in the USA, accounting for 928,741 deaths in the year 2024. Coronary artery disease (CAD) led at 40.3% of the deaths attributable to CVD, followed by stroke, other minor CVD causes …
The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and …
Type 2 diabetes mellitus (T2DM), previously referred to as non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes (MOD), represents more than 90% of all diabetes cases globally [ 1 ]. It is a complex metabolic disorder primarily …
Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.
Prof. Chantal Mathieu highlights how the absence of rigorous performance standards for continuous glucose monitors in Europe contributes to wide variability in device accuracy, raising important concerns about patient safety.
Refine the application of CGM technology in primary care to enhance the management of type 2 diabetes. Benefit from key updates and experiential learning using CGM devices, and practice your clinical decision-making skills.
Expert guidance on the multidisciplinary approach to identifying and managing chronic kidney disease in patients with type 2 diabetes, plus patient scenarios to assist your decision-making and put the latest clinical guidelines into context.
This program is not available to users in the UK and US.
Diabetes mellitus (DM) is becoming increasingly prevalent in the United States, affecting approximately 38.4 million individuals (11.6% of the population) [ 1 ]. This rise in diabetes cases spans various social, economic, and ethnic backgrounds …
Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and progressive β-cell dysfunction, resulting in impaired glucose metabolism [ 1 ]. It represents a significant public health challenge globally, with an …
Cardiovascular disease (CVD) remains the leading cause of death in the USA, accounting for 928,741 deaths in the year 2024. Coronary artery disease (CAD) led at 40.3% of the deaths attributable to CVD, followed by stroke, other minor CVD causes …
Rapid tightening of glycaemic control in individuals receiving intensive treatment for diabetes can lead to paradoxical early exacerbation of diabetic retinopathy [ 1 ]. Early worsening of diabetic retinopathy (EWDR) was first reported in …
A growing subset of patients with type 1 diabetes are developing insulin resistance, which may accelerate progression toward steatohepatitis, fibrosis, and CV complications via unique mechanisms.
A growing subset of patients with type 1 diabetes are developing insulin resistance, which may accelerate progression toward steatohepatitis, fibrosis, and CV complications via unique mechanisms.
A growing subset of patients with type 1 diabetes are developing insulin resistance, which may accelerate progression toward steatohepatitis, fibrosis, and CV complications via unique mechanisms.
Vigilance is key in people with type 1 diabetes who take tirzepatide. In this patient, ketoacidosis developed after malaise, aphagia, and malnutrition decreased his insulin requirements and he couldn’t manage his pump and sensor.
